April 20, 2026 17:00 ET  | Source: Junshi Biosciences SHANGHAI, April 20, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that early clinical results from four studies across its innovative pipeline were presented at […]

April 20, 2026 08:00 ET  | Source: Boehringer Ingelheim Limited Ingelheim, Germany, and London, UK – Boehringer Ingelheim today announced the expansion of its global Computational Innovation footprint with the launch of a new center for AI and machine learning in King’s Cross, London, UK, part of the Knowledge Quarter ecosystem. As the company continues to innovate and expand

April 17, 2026 16:01 ET  | Source: Adagene Inc. Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic

April 17, 2026 15:00 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, April 17, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced six poster presentations featuring new preclinical data from its antibody-drug conjugate (ADC) and payload

April 16, 2026 09:00 ET  | Source: Royal Philips April 16, 2026 Combining always-on spectral imaging with AI reconstruction to deliver enhanced levels of image quality, efficiency, and clinical insight across radiology, cardiology, and oncology Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received U.S. Food and Drug

First-ever demonstration of an end-to-end quantum-classical workflow for simulating complex therapeutics, unlocking a credible path to near-term quantum advantage in health April 16, 2026 08:00 ET  | Source: Wellcome Leap Inc. SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) — Wellcome Leap (Leap), a U.S. nonprofit founded by the Wellcome Trust to accelerate breakthroughs in human health, today

April 16, 2026 07:00 ET  | Source: Boehringer Ingelheim Limited This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn. Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results from the Phase 1b Beamion LUNG-1 trial of HERNEXEOS (zongertinib tablets) in treatment-naïve patients with advanced non-small cell lung

The Landmark 48th Session of the Prize Comes as the King Faisal Foundation Marks 50 Years of Impact April 15, 2026 15:19 ET  | Source: King Faisal Prize Riyadh, Saudi Arabia, April 15, 2026 (GLOBE NEWSWIRE) — On the evening of April 15, HRH Prince Turki Alfaisal, Acting Chairman of the Board of Trustees of King Faisal

April 15, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launch of Home Ground™ Schizophrenia Community, a new online platform designed to support people living with schizophrenia

April 15, 2026 08:00 ET  | Source: Boehringer Ingelheim Limited Ingelheim, Germany and Shanghai, China/Cambridge, Mass. – 15 April, 2026– Boehringer Ingelheim and Zai Lab (NASDAQ: ZLAB; HKEX: 9688) today announced a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The Phase Ib/II study will assess the safety, tolerability, and initial clinical activity of combining obrixtamig, Boehringer Ingelheim’s DLL3/CD3 T-cell engager, with zocilurtatug pelitecan (zoci; formerly ZL‑1310), Zai Lab’s DLL3-targeting ADC. The study will enroll patients with poorly differentiated NECs and extensive stage SCLC (ES-SCLC); diseases where patients urgently

April 15, 2026 08:00 ET  | Source: Callio Therapeutics SEATTLE and SINGAPORE, April 15, 2026 (GLOBE NEWSWIRE) — Callio Therapeutics, a biotherapeutics company advancing dual-payload antibody-drug conjugates (ADCs) with a targeted, multi-mechanism approach to cancer treatment, today announced a poster presentation on CLIO-8221 at the American Association of Cancer Research (AACR) Annual Meeting 2026 (April 17-22, San

Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities April 14, 2026 08:00 ET  | Source: Teva Pharmaceutical Industries Ltd SANTA BARBARA, Calif. and PARSIPPANY, N.J., April 14, 2026 (GLOBE NEWSWIRE) — Direct Relief, Teva Pharmaceuticals, and the National Association of Free and Charitable

April 14, 2026 07:00 ET  | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, April 14, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the addition of Peter Lebowitz, MD, Ph.D. to its Scientific and Strategic Advisory Board (SAB). Regarding

April 13, 2026 08:00 ET  | Source: Revolution Medicines, Inc. REDWOOD CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced positive topline results from its global, randomized, controlled Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic

April 13, 2026 06:00 ET  | Source: ProSomnus Sleep Technologies, Inc. SAN FRANCISCO, April 13, 2026 (GLOBE NEWSWIRE) — ProSomnus Sleep Technologies (“the Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy® and pioneer in Smart Sleep Medicine™, today announced that the U.S. Food and Drug Administration (FDA) has granted Class II 510(k) clearance for its RPMO₂